Leflunomid (Leflunomide)

Leflunomide blocks the enzyme dihydroorotate dehydrogenase, which is essential for de novo pyrimidine synthesis. By limiting pyrimidine production, the drug suppresses the proliferation of activated T‑lymphocytes, thereby decreasing the inflammatory activity that drives rheumatic disease.

The dosage of Leflunomid is individualized by the prescribing clinician based on the patient’s clinical status, laboratory results, and tolerance. Physicians determine the appropriate loading and maintenance doses according to current treatment guidelines.

Leflunomid is classified as pregnancy category X because it is teratogenic. It should not be used by pregnant women or women who may become pregnant. Breastfeeding is also contraindicated, as the drug can be excreted in milk and affect the infant.

To request Leflunomid, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with conventional DMARDs such as methotrexate, leflunomide offers a once‑daily oral regimen and a distinct mechanism targeting pyrimidine synthesis. It may be used as monotherapy or in combination, but clinicians consider liver safety, blood‑count effects and patient comorbidities when selecting therapy.

Leflunomid should be stored at temperatures below 25 °C, in its original packaging, and protected from moisture and direct sunlight. Maintaining these conditions helps preserve the drug’s stability and potency throughout its shelf life.

Leflunomid is taken orally, usually as a tablet, with or without food. The exact timing and any required loading dose are determined by the prescribing physician, who will also advise on any necessary laboratory monitoring.

The most serious risks include severe liver injury, bone‑marrow suppression leading to low blood counts, and teratogenic effects that can cause fetal malformations. Patients should be monitored regularly for liver enzymes, complete blood counts, and must use effective contraception.

Leflunomid is contraindicated in pregnant women, women of child‑bearing potential not using reliable contraception, patients with severe liver disease, and those with known hypersensitivity to leflunomide or its excipients. Caution is also advised for individuals with significant renal impairment.